Second allogeneic hematopoietic SCT for relapsed ALL in children

M. Kato, Y. Horikoshi, Y. Okamoto, Y. Takahashi, D. Hasegawa, K. Koh, J. Takita, M. Inoue, H. Kigasawa, A. Ogawa, Y. Sasahara, K. Kawa, H. Yabe, H. Sakamaki, R. Suzuki, Koji Kato

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4±3.7%, the cumulative incidence of relapse was 44.1±4.0% and non-relapse mortality was 18.8±3.5%. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P=0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT.

Original languageEnglish
Pages (from-to)1307-1311
Number of pages5
JournalBone Marrow Transplantation
Volume47
Issue number10
DOIs
Publication statusPublished - Oct 1 2012
Externally publishedYes

Fingerprint

Recurrence
Pediatrics
Multivariate Analysis
Tissue Donors
Survival
Mortality
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Kato, M., Horikoshi, Y., Okamoto, Y., Takahashi, Y., Hasegawa, D., Koh, K., ... Kato, K. (2012). Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplantation, 47(10), 1307-1311. https://doi.org/10.1038/bmt.2012.29

Second allogeneic hematopoietic SCT for relapsed ALL in children. / Kato, M.; Horikoshi, Y.; Okamoto, Y.; Takahashi, Y.; Hasegawa, D.; Koh, K.; Takita, J.; Inoue, M.; Kigasawa, H.; Ogawa, A.; Sasahara, Y.; Kawa, K.; Yabe, H.; Sakamaki, H.; Suzuki, R.; Kato, Koji.

In: Bone Marrow Transplantation, Vol. 47, No. 10, 01.10.2012, p. 1307-1311.

Research output: Contribution to journalArticle

Kato, M, Horikoshi, Y, Okamoto, Y, Takahashi, Y, Hasegawa, D, Koh, K, Takita, J, Inoue, M, Kigasawa, H, Ogawa, A, Sasahara, Y, Kawa, K, Yabe, H, Sakamaki, H, Suzuki, R & Kato, K 2012, 'Second allogeneic hematopoietic SCT for relapsed ALL in children', Bone Marrow Transplantation, vol. 47, no. 10, pp. 1307-1311. https://doi.org/10.1038/bmt.2012.29
Kato M, Horikoshi Y, Okamoto Y, Takahashi Y, Hasegawa D, Koh K et al. Second allogeneic hematopoietic SCT for relapsed ALL in children. Bone Marrow Transplantation. 2012 Oct 1;47(10):1307-1311. https://doi.org/10.1038/bmt.2012.29
Kato, M. ; Horikoshi, Y. ; Okamoto, Y. ; Takahashi, Y. ; Hasegawa, D. ; Koh, K. ; Takita, J. ; Inoue, M. ; Kigasawa, H. ; Ogawa, A. ; Sasahara, Y. ; Kawa, K. ; Yabe, H. ; Sakamaki, H. ; Suzuki, R. ; Kato, Koji. / Second allogeneic hematopoietic SCT for relapsed ALL in children. In: Bone Marrow Transplantation. 2012 ; Vol. 47, No. 10. pp. 1307-1311.
@article{c511edb817694c7ab42258a607ad76db,
title = "Second allogeneic hematopoietic SCT for relapsed ALL in children",
abstract = "A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4±3.7{\%}, the cumulative incidence of relapse was 44.1±4.0{\%} and non-relapse mortality was 18.8±3.5{\%}. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P=0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT.",
author = "M. Kato and Y. Horikoshi and Y. Okamoto and Y. Takahashi and D. Hasegawa and K. Koh and J. Takita and M. Inoue and H. Kigasawa and A. Ogawa and Y. Sasahara and K. Kawa and H. Yabe and H. Sakamaki and R. Suzuki and Koji Kato",
year = "2012",
month = "10",
day = "1",
doi = "10.1038/bmt.2012.29",
language = "English",
volume = "47",
pages = "1307--1311",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Second allogeneic hematopoietic SCT for relapsed ALL in children

AU - Kato, M.

AU - Horikoshi, Y.

AU - Okamoto, Y.

AU - Takahashi, Y.

AU - Hasegawa, D.

AU - Koh, K.

AU - Takita, J.

AU - Inoue, M.

AU - Kigasawa, H.

AU - Ogawa, A.

AU - Sasahara, Y.

AU - Kawa, K.

AU - Yabe, H.

AU - Sakamaki, H.

AU - Suzuki, R.

AU - Kato, Koji

PY - 2012/10/1

Y1 - 2012/10/1

N2 - A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4±3.7%, the cumulative incidence of relapse was 44.1±4.0% and non-relapse mortality was 18.8±3.5%. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P=0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT.

AB - A second SCT is generally accepted as the only potentially curative approach for ALL patients that relapse after SCT, but the role of second SCT for pediatric ALL is not fully understood. We performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. OS at 2 years was 29.4±3.7%, the cumulative incidence of relapse was 44.1±4.0% and non-relapse mortality was 18.8±3.5%. Relapse occurred faster after the second SCT than after the first SCT (117 days vs 164 days, P=0.04). Younger age (9 years or less), late relapse (180 days or more after first SCT), CR at the second SCT, and myeloablative conditioning were found to be related to longer survival. Neither acute GVHD nor the type of donor influenced the outcome of second SCT. Multivariate analysis showed that younger age and late relapse were associated with better outcomes. Our analysis suggests that second SCT for relapsed pediatric ALL is an appropriate treatment option for patients that have achieved CR, which is associated with late relapse after the first SCT.

UR - http://www.scopus.com/inward/record.url?scp=84867399702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867399702&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.29

DO - 10.1038/bmt.2012.29

M3 - Article

C2 - 22367344

AN - SCOPUS:84867399702

VL - 47

SP - 1307

EP - 1311

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -